Background: Sclerostin is a glycoprotein produced by osteocytes that is being evaluated as a potential clinical marker of bone turnover. The aim of this study was to investigate the association between neonatal vitamin D status and levels of circulating sclerostin.
Methods: Forty newborns were recruited for the study. Vitamin D deficiency was defined as a serum 25-hydroxyvitamin D3 [25(OH)D] concentration <20 ng/mL and the newborns were divided into two groups as vitamin D deficient and vitamin D sufficient groups. Calcium, phosphate, alkaline phosphatase and sclerostin were measured at birth.
Results: Newborns with vitamin D deficiency had markedly lower 25(OH)D levels than vitamin D sufficient newborns (8.5±4.4 ng/mL vs. 35.3±10.6 ng/mL, p<0.001). Vitamin D deficient infants also had significantly lower serum sclerostin levels (188.4±21.9 vs. 282.3±30.4 pg/mL; p: 0.026) than vitamin D sufficient newborns at birth. However, we did not detect a significant linear association between neonatal sclerostin and maternal/neonatal 25(OH)D levels.
Conclusions: Our data also demonstrated that vitamin D deficient newborns exhibited lower sclerostin levels than vitamin D sufficient newborns. The low sclerostin level might serve as a marker of decreased osteocyte activity in newborns with vitamin D deficiency.
No financial assistance was received in support of the study.
Conflicts of interest statement: We do not have any financial and personal relationships with other people or organizations. There are no conflicts of interest.
Ethical conduct of research: The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving newborns, informed consent has been obtained from the parents of the participants involved.
Statement of authorship: OP and GS carried out the literature review, sample size, data analysis, study design and drafted the manuscript. HC and BD helped with the design of the study, data analysis and drafting of the manuscript. All other authors participated in study design, completion of the study and finalization of the manuscript. All authors read and approved the final manuscript.
1. Sachan A, Gupta R, Das V, Agarwal A, Awasthi PK, et al. High prevalence of vitamin D deficiency among pregnant women and their newborns in northern India. Am J Clin Nutr 2005;81:1060–4.10.1093/ajcn/81.5.1060Search in Google Scholar
3. Aghajafari F, Nagulesapillai T, Ronksley PE, Tough SC, O’Beirne M, et al. Association between maternal serum 25-hydroxyvitamin D level and pregnancy and neonatal outcomes: systematic review and meta-analysis of observational studies. Br Med J 2013;346:f1169.10.1097/01.aoa.0000446336.27446.a7Search in Google Scholar
4. PascoJA, Wark JD, Carlin JB, Ponsonby AL, Vuillermin PJ, et al. Maternal vitamin D in pregnancy may influence not only offspring bone mass but other aspects of musculoskeletal health and adiposity. Med Hypotheses 2008;71:266–9.10.1016/j.mehy.2008.01.033Search in Google Scholar
5. Morley R, Carlin JB, Pasco JA, Wark JD. Maternal 25-hydroxyvitamin D and parathyroid hormone concentrations and offspring birth size. J Clin Endocrinol Metab 2006;91:906–12.10.1210/jc.2005-1479Search in Google Scholar
6. Lamberg-Allardt C, Larjosto M, Schultz E. 25-Hydroxyvitamin D concentrations in maternal and cord blood at delivery and in maternal blood during lactation in Finland. Hum Nutr Clin Nutr 1984;38:261–8.Search in Google Scholar
8. Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, et al. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 2004;35:828–35.10.1016/j.bone.2004.05.023Search in Google Scholar
9. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008;23:860−9.10.1359/jbmr.080216Search in Google Scholar
10. Krause C, Korchynskyi O, de Rooij K, Weidauer SE, de Gorter DJ, et al. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 2010;285:41614–26.10.1074/jbc.M110.153890Search in Google Scholar
11. Palomo T, Glorieux FH, Rauch F. Circulating sclerostin in children and young adults with heritable bone disorders. J Clin Endocrinol Metab 2014;99:920−5.10.1210/jc.2013-3852Search in Google Scholar
12. Ambroszkiewicz J, Rowicka G, Chełchowska M, Gajewska J, Strucińska M, et al. Serum concentrations of sclerostin and bone turnover markers in children with cow’s milk allergy. Med Wieku Rozwoj 2013;17:246–52.Search in Google Scholar
13. Dawson-Hughes B, Harris SS, Ceglia L, Palermo NJ. Effect of supplemental vitamin D and calcium on serum sclerostin levels. Eur J Endocrinol 2014;170:645−50.10.1530/EJE-13-0862Search in Google Scholar
14. Bowyer L, Catling-Paull C, Diamond T, Homer C, Davis G, et al. Vitamin D, PTH and calcium levels in pregnant women and their neonates. Clin Endocrinol (Oxf) 2009;70:372−7.10.1111/j.1365-2265.2008.03316.xSearch in Google Scholar
15. Halicioglu O, Aksit S, Koc F, Akman SA, Albudak E, et al. Vitamin D deficiency in pregnant women and their neonates in spring time in western Turkey. Paediatr Perinat Epidemiol 2012;26:53−60.10.1111/j.1365-3016.2011.01238.xSearch in Google Scholar
16. Godang K, Frøslie KF, Henriksen T, Isaksen GA, Voldner N, et al. Umbilical cord levels of sclerostin, placental weight, and birth weight are predictors of total bone mineral content in neonates. Eur J Endocrinol 2013;68:371−8.10.1530/EJE-12-0531Search in Google Scholar
18. Catalano A, Pintaudi B, Morabito N, Di Vieste G, Giunta L, et al. Gender differences in sclerostin and clinical characteristics in type 1 diabetes mellitus. Eur J Endocrinol 2014;171;293−300.10.1530/EJE-14-0106Search in Google Scholar
19. Collette NM, Genetos DC, Economides AN, Xie L, Shahnazari M, et al. Targeted deletion of Sost distal enhancer increases bone formation and bone mass. Proc Natl Acad Sci USA 2012;109:14092–7.10.1073/pnas.1207188109Search in Google Scholar
20. Lin C, Jiang X, Dai Z, Guo X, Weng T, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 2009;24:1651–61.10.1359/jbmr.090411Search in Google Scholar
21. Durosier C, Van Lierop A, Ferrari S, Chevalley T, Papapoulos S, et al. Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab 2013;98:3873−83.10.1210/jc.2013-2113Search in Google Scholar
22. Ryan ZC, Ketha H, McNulty MS, McGee-Lawrence M, Craig TA, et al. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci USA 2013;110:6199−204.10.1073/pnas.1221255110Search in Google Scholar
23. Kramer I, Loots GG, Studer A, Keller H, Kneissel M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 2010;25:178−89.10.1359/jbmr.090730Search in Google Scholar
24. Costa AG, Cremers S, Rubin MR, McMahon DJ, Sliney J, Jr, et al. Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab 2011;96:3804−10.10.1210/jc.2011-0566Search in Google Scholar
25. Young BE, McNanley TJ, Cooper EM, McIntyre AW, Witter F, et al. Vitamin D insufficiency is prevalent and vitamin D is inversely associated with parathyroid hormone and calcitriol in pregnant adolescents. J Bone Miner Res 2012;27:177−86.10.1002/jbmr.526Search in Google Scholar
©2016 by De Gruyter